Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
Titel:
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
Auteur:
Molina, Jean-Michel Clotet, Bonaventura van Lunzen, Jan Lazzarin, Adriano Cavassini, Matthias Henry, Keith Kulagin, Valeriv Givens, Naomi de Oliveira, Carlos Fernando Brennan, Clare